Active — Not RecruitingNot Applicable

Integrative Sequencing In Germline and Hereditary Tumours

Canada10 participantsStarted 2018-10-02

Plain-language summary

This study will investigate the utility of integrative sequencing of individuals and families at risk of hereditary cancer syndromes and will uncover novel contributors to tumourigenesis. Integrative sequencing refers to: 1. Whole genome sequencing (WGS) of the germline (inherited) genome 2. Whole exome sequencing (WES) or targeted/panel sequencing of tumour(s) (somatic, tumour-specific mutations) 3. DNA methylation (methylome) analysis of tumour(s) 4. RNA sequencing (transcriptome) of tumour(s) Eligible patients receiving genetic care at Princess Margaret Cancer Centre and the University Health Network may be approached by their genetic counsellor for participation in this study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must be ≥18 years of age
✓. All patients and enrolled family members must have a signed and dated informed consent form
✓. Individuals with multiple primary malignancies
✓. Families with a strong family history of cancer suggestive of a hereditary cancer syndrome
✓. Young individuals with cancer (10 years earlier than the age of onset of sporadic cases) and no identified gene mutation
✓. Rare cancer histologies

What they're measuring

Number of genomic contributors to inherited cancer through genome-wide germline analysis

Timeframe: Through study completion, up to 3 years

Number of identified novel mechanisms of tumorigenesis in hereditary cancer patients

Timeframe: Through study completion, up to 3 years

Trial details

NCT IDNCT03857594

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09

View on ClinicalTrials.gov More Hereditary Cancer Syndrome trials